Open Access Open Access  Restricted Access Subscription or Fee Access

Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework

Beatrice Setnik, PhD, Edward J. Cone, PhD

Abstract


Abuse-deterrent formulations are one strategy for mitigating the epidemic of prescription opioid abuse. Regulatory guidance documents describe the requirements for developing abuse-deterrent formulations of novel drugs and formulations; however, they do not address “abuse-deterrence equivalence” for generic formulations. As generics may be produced with different excipients and formulations compared to reference drugs, differences in their properties may impact their abuse-deterrent features. Currently, it is unclear what specific studies are needed to support generic abuse-deterrence claims. This commentary outlines several recommendations on the in vitro and in vivo testing required, including the conditions for conducting a human abuse potential study.


Keywords


abuse-deterrence equivalence, abuse-deterrent formulation, generics, opioids

Full Text:

PDF

References


Substance Abuse and Mental Health Services Administration: Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.

Vietri J, Joshi AV, Barsdorf AI, et al. Prescription opioid abuse and tampering in the United States: Results of a self-report survey. Pain Med. 2014; 15(12): 2064-2074.

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER): Guidance for Industry. Abuse-deterrent Opioids-Evaluation and Labeling. Silver Spring, MD: Office of Communications, April 2015.

Health Canada. Health Products and Food Branch: Draft Guidance Document. Tamper-Resistant Formulations of Opioid Drug Product Submissions. Ottawa, Ontario, Canada: Minister of Health, December 22, 2014.

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER): Draft Guidance for Industry. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Silver Spring, MD: Office of Communications, December 2013.

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER): Draft Guidance for Industry. Applications Covered by Section 505(b)(2). Silver Spring, MD: Office of Communications, October 1999.

Cone EJ, Giordano J, Weingarten B: An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013; 131(1-2): 100-105.

Cone EJ, Buchhalter AR, Henningfield JE, et al.: The new science of abuse-deterrence assessment of pharmaceutical products; FDA proposed guidance and category 1 laboratory studies. Pharm Anal Acta. 2014; 5(9): 317.

Health Canada. Health Products and Food Branch: Guidance Document. Clinical Assessment of Abuse Liability for Drugs with Central Nervous System Activity. Ottawa, Ontario, Canada: Minister of Health, December 7, 2007.

US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER): Draft Guidance for Industry. Assessment of Abuse Potential of Drugs. Silver Spring, MD: Office of Communications, January 2010.




DOI: https://doi.org/10.5055/jom.2016.0320

Refbacks

  • There are currently no refbacks.